newsfilter
← Latest News
GlobeNewswire·

Sol-Gel Technologies Screens First Patient for SGT-610 Phase 3 Study

SGT-610 has "Orphan Drug" designation status in the U.S. and E.U. and "Breakthrough Therapy" designation status in the U.S., as potentially the first and only therapy aimed at preventing new BCCs in Gorlin